Targeted therapy for advanced renal cell cancer (RCC): A Cochrane systematic review of published randomised trials

BJU International

Volumn 108, Issue 10, 2011, Pages 1556-1563

  Coppin, Chris ^a   Kollmannsberger, Christian ^a   Le, Lyly ^a   Porzsolt, Franz ^b   Wilt, Timothy J ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

advanced renal cell cancer; drug therapy; systematic review; targeted agents

Indexed keywords

AE 941; ALPHA INTERFERON; AMG 386; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOXYAMINOIMIDAZOLE; ERLOTINIB; EVEROLIMUS; INTERLEUKIN 2; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PAZOPANIB; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIVOZANIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; GLUCOSE BLOOD LEVEL; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INFECTION; KIDNEY CARCINOMA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; NEPHRECTOMY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80255138220     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10629.x     Document Type: Review

References (40)

1. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T,. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000; CD001425. Updated 2006
2. Linehan WM, Srinivasan R, Schmidt LS,. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7: 277-85
3. Coppin C, Le L, Porzsolt F, Wilt TJ, Kollmannsberger C,. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008; CD006017. Updated 2011 (in press)
4. Stadler WM, Rosner G, Small E, et al,. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. J Clin Oncol 2005; 23: 3726-32
5. Ratain MJ, Eisen T, Stadler WM, et al,. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12 (Pubitemid 46630627)
6. Escudier B, Choueiri TK, Oudard S, et al,. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007; 178: 1901-5 (Pubitemid 47538612)
7. Gordon MS, Manola J, Fairclough D, et al,. Low dose interferon-α2b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A phase III study of the Eastern Cooperative Oncology Group (E2898). J Clin Oncol 2004; 22 (Suppl.); abstract 4516
8. Lee CP, Patel PM, Selby PJ, et al,. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 898-903 (Pubitemid 46638842)
9. Ebbinghaus S, Hussain M, Tannir N, et al,. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 6689-95 (Pubitemid 350206805)
10. Yang JC, Haworth L, Sherry RM, et al,. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med 2003; 349: 427-34 (Pubitemid 36910021)
11. Rini BI, Halabi S, Rosenberg JE, et al,. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8
12. Escudier B, Bellmunt J, Negrier S, et al,. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-50
13. Escudier B, Eisen T, Stadler WM, et al,. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal cancer Global Evaluation Trial. J Clin Oncol 2009; 27: 3312-8
14. Escudier B, Szczylik C, Hutson TE, et al,. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-9
15. Jonasch E, Corn P, Pagliaro LC, et al,. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma. Cancer 2010; 116: 57-65
16. Bracarda S, Porta C, Boni C, et al,. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-a2a in metastatic renal cell carcinoma (RAPSODY): GOIRC study 0681. In: Genitourinary Cancers Symposium, American Society of Clinical Oncology, 2008; abstract 357
17. Procopio G, Verzoni E, Bracarda S, et al,. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 2011; 104: 1256-61
18. Rini BI, Szczylik C, Tannir NM, et al,. AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer: a randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 2011; 29 (Suppl. 7); abstract 309
19. Motzer RJ, Hutson TE, Tomczak P, et al,. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90
20. Motzer RJ, Hutson TE, Olsen MR, et al,. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT trial. J Clin Oncol 2011; 29 (Suppl. 7); abstract LBA 308
21. Sternberg CN, Davis ID, Mardiak J, et al,. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8
22. Nosov D, Bhargava P, Esteves WB, et al,. Final analysis of the phase II randomized discontinuation trial of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma. J Clin Oncol 2011; 29 (Suppl.); abstract 4550
23. Rini BI, Escudier B, Tomczak P, et al,. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma: results of phase III AXIS trial. J Clin Oncol 2011; 29 (Suppl.); abstract 4503
24. Atkins MB, Hidalgo M, Stadler WM, et al,. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-18 (Pubitemid 41103603)
25. Hudes G, Carducci M, Tomczak P, et al,. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81 (Pubitemid 46849157)
26. Motzer RJ, Escudier B, Oudard S, et al,. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372: 449-56
27. Ravaud A, Hawkins R, Gardner JP, et al,. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008; 26: 2285-91
28. Bukowski RM, Kabbinavar FF, Figlin RA, et al,. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25: 4536-41 (Pubitemid 350035309)
29. Escudier BJ, Negrier S, Gravis G, et al,. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma? Results of the randomized TORAVA phase II trial. J Clin Oncol 2010; 28 (Suppl.); abstract 4516
30. Srinivas S, Guarding AE,. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU Int 2005; 96: 536-9 (Pubitemid 41224323)
31. Madhusudan S, Protheroe A, Vasey P, et al,. A randomized phase II study of interferon alpha alone or in combination with thalidomide in metastatic renal cancer. J Clin Oncol 2004; 22 (Suppl.); abstract 4742
32. Bhargava P, Esteves B, Nosov DA, et al,. Updated activity and safety results of a phase II randomized discontinuation trial of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma. J Clin Oncol 2009; 27 (Suppl.); abstract 5032
33. Bukowski R, Cella D, Gondek K, Escudier B,. Effects of sorafenib on symptoms and quality-of-life. Results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007; 30: 220-7 (Pubitemid 46884139)
34. Cella D, Michaelson MD, Bushmakin AG, et al,. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis. Br J Cancer 2010; 102: 658-64
35. Hawkins R, Hodge R, Chen M, et al,. Renal cancer quality-of-life in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma treated with pazopanib: results from a phase III double-blind, placebo-controlled trial. Ann Oncol 2010; 21 (Suppl. 8); abstract 7119
36. Cella D, Escudier B, Rini BI, et al,. Patient-reported outcomes in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma. J Clin Oncol 2011; 29 (Suppl.); abstract 4504
37. Armstrong AJ, George DJ, Halabi S,. Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28 (Suppl.); abstract 4631
38. Kay A, Motzer R, Figlin R, et al,. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma. In: Genitourinary Cancers Symposium, American Society of Clinical Oncology, 2009; abstract 278
39. Heng DY, Xie W, Bjarnason GA, et al,. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2011; 117: 2637-42
40. Dutcher JP, de Souza P, McDermott D, et al,. Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumorhistologies. Med Oncol 2009; 26: 202-9